NextCure  Inc (NXTC)

NextCure (Nasdaq:NXTC) is a clinical-stage biopharmaceutical company focused on cancer treatments, with a market capitalization of US$28.8 million. The company recently announced a definitive merger agreement with Avere Therapeutics, Inc. for $250 million in a reverse merger transaction, expected to close in the second half of 2026. NextCure has also presented positive Phase 1 data for its SIM0505 drug in gynecologic cancers and is actively developing other antibody-drug conjugate programs while facing risks related to cash runway, share price volatility, and declining earnings forecasts.

Ikarian Capital, LLC and Neil Shahrestani have reported a beneficial ownership of 9.99% in NextCure, Inc. (NXTC), totaling 502,672 shares. This stake includes 449,369 shares that can be acquired within 60 days through warrants, which are subject to a 9.99% ownership cap. The calculation is based on 5,026,728 shares outstanding, consisting of 4,577,359 shares as of July 31, 2026, plus the warrant shares.

ADAR1 Capital Management, LLC and its sole manager Daniel Schneeberger have reported a beneficial ownership of 15.8% of NextCure, Inc.'s common stock. This ownership, totaling 722,419 shares, is held by ADAR1-managed private funds and separately managed accounts, giving both ADAR1 and Schneeberger shared voting and dispositive power. The percentage is based on 4,577,359 shares outstanding as of July 31, 2026, as per NextCure's recent Form 10-Q filing.

Squadron Master Fund LP and its related parties, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have disclosed a 1.6% equity stake in NextCure, Inc. through a SCHEDULE 13G/A SEC filing. This group beneficially owns 64,464 shares of NextCure common stock and reports shared voting and dispositive power over these shares, while explicitly disclaiming beneficial ownership under Rule 13d-4. The ownership percentage is calculated based on NextCure's outstanding shares as of May 1, 2026, plus shares from exercised pre-funded warrants.

H.C. Wainwright reiterated a Buy rating and a $20.00 price target for NextCure Inc. (NASDAQ: NXTC) following investor enthusiasm surrounding its announced reverse merger with Avere Therapeutics. The combined entity will operate as Avere Therapeutics and trade as AVRX, with the transaction expected to close in the second half of 2026. The merger is supported by significant private placements, aiming to fund Avere's operating plan and advance its clinical trials for AVR-001 in psoriasis and ulcerative colitis.